Pfizer Inc.
NYSE:PFE · New York Stock Exchange
-$0.71 today
Vol 67.91M · Avg 36.66M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
9.0%
avg 17.5%
ROIC
8.8%
avg 9.3%
ROA
3.7%
avg 7.3%
Analysis
ROE is currently the strongest return metric at 9.0% versus its period average of 17.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Albert Bourla | Chairman of the Board & Chief Executive Officer | $9.14M | — | 64 | $772,772.00 | 0.01% |
Chris Boshoff FMedSci | Chief Scientific Officer and President of Research & Development | $5.20M | — | 62 | $0.00 | <0.01% |
Aamir Malik | Executive Vice President & Chief U.S. Commercial Officer | $4.90M | — | 50 | $194,883.00 | <0.01% |
David Denton | Executive Vice President & Chief Financial Officer | $4.80M | — | 61 | $216,537.00 | <0.01% |
Douglas Lankler | Executive Vice President & Chief Legal Officer | $4.62M | — | 60 | $194,883.00 | <0.01% |
Dennis Hancock | Executive VP & Chief Information Officer | — | — | — | $0.00 | <0.01% |
Francesca DeMartino | Chief Investor Relations Officer | — | — | — | — | — |
Jennifer Damico | Senior Vice President, Controller & Principal Accounting Officer | — | — | 57 | $31,397.00 | <0.01% |
Payal Sahni Becher | Chief People Experience Officer & Executive Vice President | — | — | 51 | $108,268.00 | <0.01% |
Michael S. Vincent | Senior Vice President and Chief Scientific Officer of Inflammation & Immunology | — | — | — | $0.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
1
$51,400.00
Net Sentiment
$51,400.00
Net selling
Most Active
DAMICO JENNIFER B.
1 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 1 sells worth $51,400.00 over the last 12 months. That adds up to net selling of $51,400.00. DAMICO JENNIFER B. was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -5.1% | +5.3% (15yr)5 analysts |
| Revenue | N/A | N/A | -3.7% | +0.7% (15yr)11 analysts |
| Net Income | N/A | N/A | -10.7% | +4.6% (15yr)11 analysts |
| EBIT | N/A | N/A | -9.7% | -1.0% (15yr)11 analysts |
Analysis
Recent growth has been strongest in Revenue at -3.7% over three years. Forward estimates point to EPS at +5.3% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Merck & Co., Inc.
NYSE:MRK
$281.98B
Novo Nordisk A/S
NYSE:NVO
$191.08B
Amgen Inc.
NASDAQ:AMGN
$180.62B
Gilead Sciences, Inc.
NASDAQ:GILD
$152.45B
Danaher Corporation
NYSE:DHR
$125.44B
Stryker Corporation
NYSE:SYK
$119.08B
Bristol-Myers Squibb Company
NYSE:BMY
$109.87B
GSK plc
NYSE:GSK
$101.83B
Sanofi
NASDAQ:SNY
$101.45B
Boston Scientific Corporation
NYSE:BSX
$67.35B
Who manages PFE?
Pfizer Inc. (PFE) lists 10 active executives. The top listed executive is David Denton, Executive Vice President & Chief Financial Officer.
Are PFE insiders buying or selling?
Recent insider activity shows net buying of $124.31M.
Explore More
Continue the stock analysis
Jump to another research area for this company.